Cargando…
PERFUSE: a French non-interventional study of patients with inflammatory bowel disease receiving infliximab biosimilar SB2: a 12-month analysis
BACKGROUND: Flixabi(TM) (SB2) is a biosimilar of the reference infliximab (IFX), Remicade(®). Published evidence on long-term, real-world use of SB2 in patients either IFX naive or transitioned from prior IFX is scarce. OBJECTIVES: We evaluated persistence, effectiveness, and safety of SB2 over 12 m...
Autores principales: | Bouhnik, Yoram, Fautrel, Bruno, Beaugerie, Laurent, Pelletier, Anne-Laure, Martinez-Vinson, Christine, Freudensprung, Ulrich, Brigui, Amira, Addison, Janet |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10021102/ https://www.ncbi.nlm.nih.gov/pubmed/36936799 http://dx.doi.org/10.1177/17562848221145654 |
Ejemplares similares
-
Real-world evidence of the use of the infliximab biosimilar SB2: data from the PERFUSE study
por: Fautrel, Bruno, et al.
Publicado: (2023) -
PERFUSE: Non-Interventional Cohort Study of Patients Receiving Infliximab Biosimilar SB2: Results in Pediatric Patients
por: Martinez-Vinson, Christine, et al.
Publicado: (2022) -
Real-World Evidence on Etanercept Biosimilar SB4 in Etanercept-Naïve or Switching Patients: A Systematic Review
por: Ebbers, Hans C., et al.
Publicado: (2019) -
Batch-to-Batch Consistency of SB4 and SB2, Etanercept and Infliximab Biosimilars
por: Ebbers, Hans C., et al.
Publicado: (2020) -
Physicochemical and biological characterization of SB2, a biosimilar of Remicade® (infliximab)
por: Hong, Juyong, et al.
Publicado: (2016)